GLP-1 Market Report 2026: Size, Growth & Key Players

Introduction

The GLP-1 receptor agonist class went from a diabetes niche to the fastest-growing drug category in pharma history in under five years. Global sales for semaglutide and tirzepatide alone cleared $50 billion in 2024, and analysts at J.P. Morgan, Goldman Sachs, and Morgan Stanley have all published reports putting the obesity and cardiometabolic GLP-1 market between $130 billion and $200 billion by 2030.

That kind of growth has reshaped the entire industry. Novo Nordisk briefly became the most valuable company in Europe. Eli Lilly crossed an $800 billion market cap. Roche, Pfizer, AstraZeneca, Amgen, and Viking Therapeutics all rushed to build pipelines. Compounding pharmacies and telehealth platforms (TrimRx among them) carved out a parallel market while supply shortages persisted.

This report breaks down where the GLP-1 market sits in 2026, which companies are winning, what the pipeline looks like, and what the next inflection points are.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

How Big Is the GLP-1 Market in 2026?

The GLP-1 receptor agonist class is the largest single therapeutic category in pharma by sales growth. Combined 2024 revenue for Novo Nordisk’s semaglutide franchise (Ozempic®, Wegovy®, Rybelsus®) and Eli Lilly’s tirzepatide (Mounjaro®, Zepbound®) reached roughly $52 billion, per company 10-K filings.

Quick Answer: Global GLP-1 sales topped $50 billion in 2024, with Novo Nordisk and Eli Lilly capturing roughly 95% of branded revenue

Novo Nordisk reported $25.4 billion in semaglutide sales in 2024 across its three brand SKUs. Eli Lilly reported $16.5 billion in tirzepatide sales across Mounjaro and Zepbound, up from $5.1 billion in 2023. Older agents like liraglutide (Victoza®, Saxenda®), dulaglutide (Trulicity®), and exenatide (Byetta, Bydureon) contributed another $5 to 7 billion combined.

The 2024 to 2025 growth rate was over 60% year over year. That is unusual for any drug class once it crosses $20 billion in annual sales. The Pfizer-Lipitor era peaked around $13 billion. Humira at its peak hit $21 billion.

Why Has the GLP-1 Market Grown So Fast?

Three things drove the explosion: better drugs, broader indications, and stronger evidence.

The original GLP-1 agonists in the 2000s (exenatide, liraglutide) required daily injections and produced about 5 to 7% weight loss. Semaglutide changed that. STEP 1 (Wilding et al. 2021 NEJM) showed 14.9% mean weight loss at 68 weeks in adults with obesity, a result no oral or injectable weight-loss drug had ever matched. SURMOUNT-1 then pushed tirzepatide past 20%.

At the same time, label expansion accelerated. Semaglutide picked up a cardiovascular indication via SELECT, a kidney indication via FLOW, and is in phase 3 for MASH (ESSENCE). Tirzepatide picked up an OSA indication via SURMOUNT-OSA in December 2024 and is in late-stage trials for heart failure with preserved ejection fraction.

Coverage followed. CMS allowed semaglutide for cardiovascular risk reduction in Medicare Part D in 2024. Private insurers expanded obesity coverage as employer demand climbed.

Who Are the Biggest GLP-1 Players?

Two companies dominate. Novo Nordisk and Eli Lilly accounted for roughly 95% of branded GLP-1 revenue in 2024. The remaining 5% is split among older agents (Sanofi’s lixisenatide, AstraZeneca’s exenatide, GSK’s albiglutide before discontinuation) and generic liraglutide.

Novo Nordisk’s franchise rests on semaglutide. Ozempic is approved for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus is the oral 14 mg pill version. CagriSema (semaglutide plus cagrilintide) is in phase 3 with mixed readouts so far. Amycretin is the next-generation candidate in phase 1 to 2.

Eli Lilly’s tirzepatide franchise rests on a dual GIP/GLP-1 receptor agonist mechanism. Mounjaro is the diabetes brand, Zepbound the obesity brand. Retatrutide, a triple agonist hitting GLP-1, GIP, and glucagon receptors, posted 24% mean weight loss at 48 weeks in phase 2 (Jastreboff et al. 2023 NEJM) and is in phase 3 now. Orforglipron is the oral non-peptide GLP-1 candidate in phase 3.

Compounded versions filled supply gaps during the FDA-recognized shortage period and are still available through state-licensed 503A pharmacies under personalized prescriptions. TrimRx is one of the telehealth platforms working with these pharmacies.

What Is the 2030 GLP-1 Market Forecast?

Most analyst forecasts cluster between $130 billion and $200 billion for the global GLP-1 market by 2030, with obesity making up the largest share.

Goldman Sachs published a $130 billion 2030 estimate in 2023, then revised it upward to $150 billion in 2024. Morgan Stanley’s mid-2024 estimate was $144 billion. J.P. Morgan put the high end at $200 billion if oral GLP-1s reach mass adoption.

The obesity share alone is projected at $100 billion or more. Diabetes, MASH, sleep apnea, kidney disease, heart failure, and emerging indications (Alzheimer’s, addiction, PCOS) make up the rest.

Two big swing factors: how fast oral pills replace injections, and how aggressively governments fund obesity coverage. CMS, the UK NHS, and several European single-payer systems are all actively reviewing reimbursement.

What Does the GLP-1 Pipeline Look Like?

The pipeline is unusually deep for a class that already has approved drugs. More than 20 candidates are in phase 2 or phase 3 as of early 2026.

Eli Lilly leads in pipeline diversity. Retatrutide (triple agonist) is in phase 3 obesity and MASH trials. Orforglipron (oral small molecule GLP-1) is in phase 3 obesity and diabetes. Eloralintide is an amylin analog in early development.

Novo Nordisk has CagriSema (phase 3), amycretin (oral and injectable in phase 1 to 2), and a long-acting monthly GLP-1 candidate called NN9487.

Outside the two leaders, Viking Therapeutics has VK2735 (dual GIP/GLP-1) in phase 2 with strong early data. Amgen has MariTide (dual GLP-1 receptor agonist plus GIP receptor antagonist) in phase 2 with monthly dosing. Roche acquired Carmot Therapeutics in 2023 for $2.7 billion and now has CT-388 in phase 2. Pfizer’s danuglipron program shut down in 2023 to 2024 after liver safety concerns, but a new candidate is in early trials. AstraZeneca licensed ECC5004 from Eccogene and has an obesity pipeline in development.

How Is Patient Access Changing?

Access has been the binding constraint since 2022. Demand for semaglutide and tirzepatide outstripped manufacturing for nearly three years, leading the FDA to designate both as official shortage drugs.

The FDA removed tirzepatide from the shortage list in October 2024 and removed semaglutide in February 2025. That triggered enforcement against unauthorized mass compounding, though state-licensed 503A pharmacies can still produce personalized prescriptions for individual patients under valid clinical justification.

Cash-pay prices for branded products remain high. Wegovy and Zepbound list prices sit around $1,000 to $1,350 per month before insurance. Novo Nordisk and Eli Lilly both launched direct-to-consumer programs in 2024 with discounted vial pricing around $349 to $499 monthly for self-pay patients.

Compounded GLP-1s through telehealth platforms typically run $179 to $499 per month, depending on the dose and pharmacy. TrimRx offers a free assessment quiz to determine clinical eligibility and personalized treatment plans based on each patient’s health history.

How Are Insurance Trends Shifting?

Insurance coverage for GLP-1s is in active flux. The big shift in 2024 to 2025 was Medicare’s decision to allow semaglutide reimbursement for cardiovascular risk reduction in patients with established disease and obesity, following the SELECT trial.

That ruling did not open Medicare to general weight-loss coverage. The 2003 Medicare Modernization Act still blocks coverage for drugs used solely for weight loss. Congress has considered the Treat and Reduce Obesity Act multiple times without passing it.

Private insurance is mixed. Some employer plans dropped coverage in 2024 to 2025 as utilization spiked and costs climbed. Others added coverage tied to BMI cutoffs, prior authorization, and step therapy. Express Scripts, CVS Caremark, and OptumRx all publish updated formulary tiers each quarter.

State Medicaid coverage varies. As of early 2026, roughly 16 states cover GLP-1s for obesity beyond diabetes, per the Kaiser Family Foundation tracker.

What Happens When These Drugs Go Generic?

Semaglutide’s main US composition-of-matter patent expires in late 2031, with formulation and method-of-use patents extending later in select markets. Tirzepatide’s main patent runs to roughly 2036.

Generic semaglutide manufacturing is already underway in countries with earlier patent expirations. India’s Cipla and Dr. Reddy’s, and Brazil’s EMS have all announced plans for biosimilar or generic versions, with launches expected in some markets as early as 2026 to 2027.

Once US generics arrive, prices typically drop 60 to 90% within two to three years. That would put a 30-day supply of semaglutide in the $50 to $150 range eventually, dramatically expanding access. The catch is that GLP-1s are peptide drugs requiring complex synthesis and sterile injectable production, so the price drop is likely to be slower than small-molecule generics.

Key Takeaway: Analyst consensus puts the 2030 GLP-1 market at $130-200 billion, driven by obesity, MASH, sleep apnea, kidney disease, and cardiovascular indications

How Are Competitors Trying to Win?

Three strategies are visible: oral formulations, less-frequent dosing, and combination products.

Oral GLP-1s could change the market. Rybelsus is already approved but produces less weight loss than injectables. Orforglipron is a true oral small molecule that does not require strict fasting and has shown phase 2 weight loss in the 14 to 15% range. If approved with a clean label, it could expand the market significantly because patient resistance to injections is real.

Monthly dosing is the second front. Amgen’s MariTide is the leading candidate at a once-monthly subcutaneous injection. Novo Nordisk’s NN9487 is also in development. Monthly dosing reduces adherence issues and side effect frequency.

Combination products go beyond GLP-1 alone. CagriSema combines semaglutide with cagrilintide (an amylin analog). Retatrutide triples up. Bimagrumab plus semaglutide combinations are in early study to preserve muscle mass during weight loss.

What Are the Biggest Market Risks?

Five risks dominate analyst notes.

Manufacturing capacity is still tight. Novo Nordisk and Eli Lilly have spent more than $20 billion combined on new fill-finish and API capacity since 2023, but demand keeps pulling ahead.

Insurance pushback is the second risk. Several large employer plans cut coverage in 2025 citing cost. PBMs are negotiating harder. CMS has not opened general weight-loss coverage. If coverage erodes, branded volume could plateau even with strong clinical evidence.

Side effect concerns are the third. GLP-1s cause GI side effects in 40 to 60% of users in trials. Rare events like pancreatitis, gallbladder disease, and thyroid C-cell tumors remain in the labels. Lawsuits have been filed but courts have not consolidated them.

Muscle loss and rebound weight gain are the fourth risk. Trials show that stopping therapy leads to weight regain. The STEP 1 extension showed about two-thirds of lost weight returned within one year of stopping. This raises questions about lifetime therapy economics.

Generic and biosimilar pressure is the fifth. Semaglutide loses key patents in 2031 to 2033 across major markets. That timeline is closer than many investors price in.

How Is the Telehealth GLP-1 Market Evolving?

Telehealth-based GLP-1 prescribing went from a tiny niche to a multi-billion dollar segment between 2022 and 2025. Hims & Hers, Ro, Noom, WeightWatchers, and dozens of smaller platforms (TrimRx, Henry Meds, Mochi Health, Found, Sequence) all entered the category.

Pricing is competitive. Self-pay monthly costs for compounded semaglutide and tirzepatide typically range from $179 to $499 depending on dose. The compounded supply chain runs through state-licensed 503A pharmacies under personalized prescriptions written after a telehealth clinical evaluation.

The category got more regulated after the FDA shortage designation ended. Mass compounding by outsourcing facilities was restricted, but 503A patient-specific compounding remains legal where clinically justified. The telehealth platforms still operating have leaned into longer clinical intake processes and ongoing monitoring.

TrimRx positions toward clinical depth rather than fastest-checkout. The free assessment quiz routes patients through a medical questionnaire reviewed by licensed providers before any prescription is issued.

How Is Global Access Changing in 2026?

Outside the United States, GLP-1 access in 2026 looks dramatically different. The UK’s NICE approved Wegovy for NHS use in 2023 but restricted reimbursement to specialist weight management services, capping treatment at two years and limiting access to roughly 35,000 patients in the initial rollout. Demand far exceeded supply, and waiting lists for tier 3 weight management services stretched past 18 months in some regions in 2025.

Germany made Wegovy available in 2023 but ended export restrictions only in 2024. The country’s statutory health insurance (GKV) does not cover anti-obesity medications, leaving patients to pay cash at roughly €270 per month for a starter dose.

Japan approved Wegovy in March 2023 with launch in 2024. The drug is covered under Japan’s universal health insurance for patients meeting specific BMI and comorbidity criteria, with prices set by the central drug pricing council at roughly ¥20,000 per month.

China’s pathway is the most interesting development of 2025 and 2026. Novo Nordisk’s semaglutide is approved for diabetes (Ozempic) but not obesity. Eli Lilly received tirzepatide approval for both diabetes and obesity in China in 2024. Several Chinese manufacturers including Innovent Biologics, Hengrui Pharmaceuticals, and Sciwind Biosciences have phase 3 programs for GLP-1s targeted at Chinese populations, with several launches expected in 2026 and 2027.

India approved tirzepatide for diabetes in March 2025 and obesity in mid-2025. Cipla and Lupin have filed for generic semaglutide following Canadian patent expiry. India’s domestic market for GLP-1 therapy is expected to grow from roughly $50 million in 2024 to $1 billion or more by 2028.

The global story creates a long-tailed growth opportunity. The US dominates revenue, but volume growth in the next decade will increasingly come from international markets where pricing is lower but patient populations are vastly larger.

What Does Manufacturing Capacity Actually Look Like?

Manufacturing capacity has been the limiting factor for the GLP-1 market since 2022. Both leading manufacturers have committed massive capital to scale up:

Eli Lilly announced more than $20 billion in manufacturing investment between 2022 and 2025, including a $9 billion facility in Lebanon, Indiana, expansions to its Concord, North Carolina campus, and new sites in Limerick, Ireland and Alzey, Germany. The company also acquired the Nexus Pharmaceuticals injectable manufacturing facility in 2024 for $924 million.

Novo Nordisk announced approximately $20 billion in manufacturing capacity expansion through 2027, with major investments in Bagsvaerd and Hillerod (Denmark), Clayton (North Carolina), and Chartres (France). The parent Novo Holdings acquired Catalent for $16.5 billion in late 2024, then sold three Catalent fill-finish sites to Novo Nordisk for $11 billion to dedicate that capacity to GLP-1 production.

The bottleneck is increasingly device assembly rather than active pharmaceutical ingredient production. The auto-injector pens used for weekly dosing require specialized fill-finish lines that are slow to build. Vial-based formulations like Lilly’s LillyDirect Zepbound vials can be produced through more flexible manufacturing routes and have helped both companies expand cash-pay supply.

By late 2025 the FDA had removed both semaglutide and tirzepatide from the shortage list, signaling that supply had caught up to demand at current price levels. Any large expansion of insurance coverage in 2026 to 2027 could re-tighten supply, particularly for branded auto-injector formulations.

What Does the GLP-1 Market Mean for Healthcare Costs Overall?

The macro impact of GLP-1 spending on US healthcare costs is now visible in payer data. A Peterson-KFF Health System Tracker analysis released in late 2024 estimated GLP-1 drugs added roughly 1.5% to total US prescription drug spending growth in 2023 and projected 2 to 4% addition annually through 2028.

Whether GLP-1 spending pays for itself in reduced complications remains an open question. The SELECT trial showed a 20% reduction in major adverse cardiovascular events but cost-effectiveness analyses published in JAMA Internal Medicine and Annals of Internal Medicine in 2024 produced mixed results. The Institute for Clinical and Economic Review (ICER) concluded in its 2023 assessment that semaglutide for weight management was cost-effective at $7,500 to $9,800 per year but not at the current $13,000+ US list price.

For patients and physicians making treatment decisions in 2026, the macro debate matters less than the individual clinical question: does this patient benefit enough from GLP-1 therapy to justify the cost and the side effect profile? Trial data on weight loss, cardiovascular outcomes, diabetes prevention, kidney protection, and sleep apnea improvement provide the answer for many patients. The cost question gets answered through insurance coverage, manufacturer direct programs, or licensed compounding telehealth services like TrimRx.

Bottom line: More than 20 oral, weekly, and monthly GLP-1, amylin, and triple-agonist candidates are in late-stage trials as of early 2026

FAQ

How Much Did Novo Nordisk Make From Ozempic in 2024?

Novo Nordisk reported $17.5 billion in Ozempic sales for 2024 and $25.4 billion across the full semaglutide franchise including Wegovy and Rybelsus. Year-over-year growth for Ozempic alone was about 26%.

Is Eli Lilly Bigger Than Novo Nordisk in GLP-1s Now?

In dollar terms Novo Nordisk still leads, but Eli Lilly is growing faster. Tirzepatide sales tripled from 2023 to 2024 and could surpass total semaglutide sales by 2027 to 2028 if current growth holds, per Goldman Sachs and BMO Capital projections.

When Will Retatrutide Be Approved?

Eli Lilly has guided phase 3 retatrutide obesity readouts for 2026 with a potential FDA filing in late 2026 or 2027. Approval would likely come in 2027 to 2028 if data hold.

What Is the Cheapest Legitimate GLP-1 in 2026?

The cheapest legitimate options are compounded semaglutide through state-licensed 503A pharmacies (often $179 to $299 monthly) or Novo’s and Lilly’s direct-to-consumer vial programs ($349 to $499 monthly for self-pay).

Will Medicare Cover Weight-loss GLP-1s?

Not yet for weight loss alone. CMS opened semaglutide coverage in 2024 for patients with established cardiovascular disease and overweight or obesity, based on SELECT. Broader weight-loss coverage requires either Congressional action on the Treat and Reduce Obesity Act or new CMS interpretation.

Are Oral GLP-1 Pills as Effective as Injections?

Not yet. Rybelsus produces about 4 to 5% weight loss at the 14 mg dose. Phase 3 orforglipron data are still pending but phase 2 showed 14 to 15% weight loss, which is closer to injectable semaglutide. Phase 3 readouts are expected in 2026.

What Is the Biggest Threat to the GLP-1 Market?

Insurance coverage decisions are the biggest near-term swing factor. Patent expiration in the early 2030s and any major safety signal would be the bigger longer-term risks.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.